Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Completed · Has a placebo group

Conditions studied: Fragile X Syndrome

In brief

The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.

Key facts

Study ID
NCT00823368
Run by
Seaside Therapeutics, Inc.
Starts
2009-01-01
Last updated by the study team
2013-07-31

Who can join

Age: 6 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.